Skip to main content
SpringerLink
Log in

Melanoma

  • Chapter
  • First Online:
A Practical Guide to Skin Cancer

  • 1377 Accesses

Abstract

Melanoma most commonly presents as a new or changing pigmented lesion on sun exposed skin. The skin cancer can be categorized into varying subtypes based on its clinical appearance and anatomical location. The prognosis is similar amongst the subtypes with tumor thickness as the most important factor for survival. Melanoma staging depends upon the patient’s symptoms, clinical exam and clinician’s index of suspicion. Surgery is the first line treatment for localized melanoma. Advances in tumor genetics and immunology have led to the development of targeted therapies for metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10(11):1811–23. https://doi.org/10.1586/era.10.170.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bradford PT, Anderson WF, Purdue MP, Goldstein AM, Tucker MA. Rising melanoma incidence rates of the trunk among younger women in the United States. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19(9):2401–6. https://doi.org/10.1158/1055-9965.epi-10-0503.

    Article  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.

    Article  PubMed  Google Scholar 

  4. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, Wiggins CL, Wingo PA. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S17-25.e11–3. https://doi.org/10.1016/j.jaad.2011.04.032.

    Article  Google Scholar 

  5. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47. https://doi.org/10.1056/NEJMoa050092.

    Article  PubMed  CAS  Google Scholar 

  6. Millington GW. Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54). Clin Exp Dermatol. 2013;38(2):222–3. https://doi.org/10.1111/ced.12015.

    Article  PubMed  CAS  Google Scholar 

  7. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66(20):9818–28. https://doi.org/10.1158/0008-5472.can-06-0494.

    Article  PubMed  CAS  Google Scholar 

  8. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340–6. https://doi.org/10.1200/JCO.2006.06.2984.

    Article  PubMed  CAS  Google Scholar 

  9. Bello DM, Ariyan CE, Carvajal RD. Melanoma mutagenesis and aberrant cell signaling. Cancer Control. 2013;20(4):261–81.

    Article  PubMed  Google Scholar 

  10. Parkin DM, Mesher D, Sasieni P. 13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer. 2011;105(Suppl 2):S66–9. https://doi.org/10.1038/bjc.2011.486.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pfahlberg A, Kolmel KF, Gefeller O, Febim Study G. Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation- induced melanoma. Br J Dermatol. 2001;144(3):471–5.

    Article  CAS  PubMed  Google Scholar 

  12. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257–63. https://doi.org/10.1200/JCO.2010.28.7078.

    Article  PubMed  CAS  Google Scholar 

  13. Ghivasand R, Ruegg CS, Welderpass E, Green AC, Lund E, Velerod MB. Indoor tanning and melanoma risk: long-term evidence from a Prospective Population Based Cohort Study. Am J Epidemol. 2017;185(3):147–56.

    Google Scholar 

  14. Friedman RJ, Farber MJ, Warycha MA, Papathasis N, Miller MK, Heilman ER. The "dysplastic" nevus. Clin Dermatol. 2009;27(1):103–15. https://doi.org/10.1016/j.clindermatol.2008.09.008.

    Article  PubMed  Google Scholar 

  15. Silva JH, Sa BC, Avila AL, Landman G, Duprat Neto JP. Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma – review article. Clinics (Sao Paulo). 2011;66(3):493–9.

    Article  Google Scholar 

  16. Nestle FO, Burg G, Dummer R. New perspectives on immunobiology and immunotherapy of melanoma. Immunol Today. 1999;20(1):5–7.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang M, Graor H, Yan L, Kim J. Identification of melanoma-reactive CD4+ T-cell subsets from human melanoma draining lymph nodes. J Immunother. 2016;39(1):15–26. https://doi.org/10.1097/CJI.0000000000000103.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin. 1985;35:130–51.

    Article  CAS  PubMed  Google Scholar 

  19. Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, Kopf AW, Polsky D. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;29(22):2771–6.

    Article  Google Scholar 

  20. Grob JJ, Bonerandi JJ. The ‘ugly duckling’ sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998;134(1):103–4.

    Article  CAS  PubMed  Google Scholar 

  21. Mar V, Roberts H, Wolfe R, English DR, Kelly JW. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol. 2013;68(4):568–75. https://doi.org/10.1016/j.jaad.2012.09.047.

    Article  PubMed  Google Scholar 

  22. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC Jr, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database. J Clin Oncol. 2011;29(16):2199–205. https://doi.org/10.1200/JCO.2010.31.5812.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Jen M, Murphy M, Grant-Kels JM. Childhood melanoma. Clin Dermatol. 2009;27(6):529–36. https://doi.org/10.1016/j.clindermatol.2008.09.011.

    Article  PubMed  Google Scholar 

  24. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159(3):669–76. https://doi.org/10.1111/j.1365-2133.2008.08713.x.

    Article  PubMed  CAS  Google Scholar 

  25. Gallegos-Hernandez JF, Ortiz-Maldonado AL, Minauro-Munoz GG, Arias-Ceballos H, Hernandez-Sanjuan M. Dermoscopy in cutaneous melanoma. Cir Cir. 2015;83(2):107–11. https://doi.org/10.1016/j.circir.2015.04.004.

    Article  PubMed  Google Scholar 

  26. Menzies SW, Moloney FJ, Byth K, Avramidis M, Argenziano G, Zalaudek I, Braun RP, Malvehy J, Puig S, Rabinovitz HS, Oliviero M, Cabo H, Bono R, Pizzichetta MA, Claeson M, Gaffney DC, Soyer HP, Stanganelli I, Scolyer RA, Guitera P, Kelly J, McCurdy O, Llambrich A, Marghoob AA, Zaballos P, Kirchesch HM, Piccolo D, Bowling J, Thomas L, Terstappen K, Tanaka M, Pellacani G, Pagnanelli G, Ghigliotti G, Ortega BC, Crafter G, Ortiz AM, Tromme I, Karaarslan IK, Ozdemir F, Tam A, Landi C, Norton P, Kacar N, Rudnicka L, Slowinska M, Simionescu O, Di Stefani A, Coates E, Kreusch J. Dermoscopic evaluation of nodular melanoma. JAMA Dermatol. 2013;149(6):699–709. https://doi.org/10.1001/jamadermatol.2013.2466.

    Article  PubMed  Google Scholar 

  27. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, Tsao H, Barbosa VH, Chuang TY, Duvic M, Ho VC, Sober AJ, Beutner KR, Bhushan R, Smith Begolka W, American Academy of Dermatology. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol. 2011;65(5):1032–47. https://doi.org/10.1016/j.jaad.2011.04.031.

    Article  PubMed  Google Scholar 

  28. Hendi A, Brodland DG, Zitelli JA. Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch Dermatol. 2006;142(7):871–6. https://doi.org/10.1001/archderm.142.7.871.

    Article  PubMed  Google Scholar 

  29. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol. 2012;67(1):1.e1–16. quiz 17–8. https://doi.org/10.1016/j.jaad.2012.02.047.

    Article  Google Scholar 

  30. Patrawala S, Maley A, Greskovich C, Stuart L, Parker D, Swerlick R, Stoff B. Discordance of histopathologic parameters in cutaneous melanoma: clinical implications. J Am Acad Dermatol. 2016;74(1):75–80. https://doi.org/10.1016/j.jaad.2015.09.008.

    Article  PubMed  Google Scholar 

  31. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34. https://doi.org/10.1200/JCO.2001.19.16.3622.

    Article  CAS  PubMed  Google Scholar 

  32. Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol. 2006;19(Suppl 2):S34–40. https://doi.org/10.1038/modpathol.3800508.

    Article  PubMed  Google Scholar 

  33. Schmitt FC, Bacchi CE. S-100 protein: is it useful as a tumour marker in diagnostic immunocytochemistry? Histopathology. 1989;15(3):281–8.

    Article  CAS  PubMed  Google Scholar 

  34. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123(2):195–203.

    PubMed  PubMed Central  CAS  Google Scholar 

  35. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35(5):433–44. https://doi.org/10.1111/j.1600-0560.2007.00891.x.

    Article  PubMed  Google Scholar 

  36. Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol. 2001;44(2):188–92. https://doi.org/10.1067/mjd.2001.110067.

    Article  PubMed  CAS  Google Scholar 

  37. Gershenwald JE, Scolyr RA, Hess KR, et al. Melanoma of the skin. In: Amin MD, editor. AJCC cancer staging manual. 8th ed. Chicago: American Joint Committee on Cancer; 2017. p. 563.

    Chapter  Google Scholar 

  38. Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014;32:2479.

    Article  PubMed  Google Scholar 

  39. Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, Halpern AC. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med. 1996;125(5):369–75.

    Article  CAS  PubMed  Google Scholar 

  40. Wang TS, Johnson TM, Cascade PN, Redman BG, Sondak VK, Schwartz JL. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol. 2004;51(3):399–405. https://doi.org/10.1016/j.jaad.2004.02.017.

    Article  PubMed  Google Scholar 

  41. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E, Kraybill WG, McKinnon JG, Wang HJ, Elashoff R, Faries MB, MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370(7):599–609. https://doi.org/10.1056/NEJMoa1310460.

    Article  CAS  PubMed  Google Scholar 

  42. Biddle DA, Evans HL, Kemp BL, El-Naggar AK, Harvell JD, White WL, Iskandar SS, Prieto VG. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol. 2003;27(5):673–81.

    Article  PubMed  Google Scholar 

  43. Carson KF, Wen DR, Li PX, Lana AM, Bailly C, Morton DL, Cochran AJ. Nodal nevi and cutaneous melanomas. Am J Surg Pathol. 1996;20(7):834–40.

    Article  CAS  PubMed  Google Scholar 

  44. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ, MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–1317. https://doi.org/10.1056/NEJMoa060992.

    Article  CAS  PubMed  Google Scholar 

  45. Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, GC D. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006;13(6):809–16. https://doi.org/10.1245/ASO.2006.03.058.

    Article  PubMed  Google Scholar 

  46. Kingham TP, Panageas KS, Ariyan CE, Busam KJ, Brady MS, Coit DG. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol. 2010;17(2):514–20. https://doi.org/10.1245/s10434-009-0836-3.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Faries MB, Thompson JF, Andtbacka RH, Mozzillo N, et al. Complete dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Torjesen I. Sentinel node biopsy for melanoma: unnecessary treatment? BMJ. 2013;346:e8645. https://doi.org/10.1136/bmj.e8645.

    Article  PubMed  Google Scholar 

  49. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206. https://doi.org/10.1200/JCO.2009.23.4799.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Schild SE. Role of radiation therapy in the treatment of melanoma. Expert Rev Anticancer Ther. 2009;9(5):583–6. https://doi.org/10.1586/era.09.21.

    Article  PubMed  CAS  Google Scholar 

  51. Samlowski WE, Watson GA, Wang M, Rao G, Klimo P Jr, Boucher K, Shrieve DC, Jensen RL. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109(9):1855–62. https://doi.org/10.1002/cncr.22605.

    Article  PubMed  Google Scholar 

  52. Fuhrmann D, Lippold A, Borrosch F, Ellwanger U, Garbe C, Suter L. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? Br J Dermatol. 2001;144(1):66–70.

    Article  CAS  PubMed  Google Scholar 

  53. Yang AS, Chapman PB. The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am. 2009;23(3):583–597, x. https://doi.org/10.1016/j.hoc.2009.03.006.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Kroon HM. Treatment of locally advanced melanoma by isolated limb infusion with cytotoxic drugs. J Skin Cancer. 2011;2011:106573. https://doi.org/10.1155/2011/106573.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Zloza A, Dharmadhikari ND, Huelsmann EJ, Broucek JR, Hughes T, Kohlhapp FJ, Kaufman HL. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunol Immunother. 2017;66(1):9–16. https://doi.org/10.1007/s00262-016-1916-4.

    Article  PubMed  CAS  Google Scholar 

  56. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16(11 Suppl 13):11–20.

    Google Scholar 

  57. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29(4):241–52.

    Article  CAS  PubMed  Google Scholar 

  58. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89(6–7):884–93. https://doi.org/10.1016/j.biochi.2007.04.006.

    Article  PubMed  CAS  Google Scholar 

  59. Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist. 2003;8(5):451–8.

    Article  CAS  PubMed  Google Scholar 

  60. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. https://doi.org/10.1056/NEJMoa1003466.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. https://doi.org/10.1200/JCO.2014.56.2736.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. https://doi.org/10.1056/NEJMoa1104621.

    Article  PubMed  CAS  Google Scholar 

  63. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–9. https://doi.org/10.1001/jama.2016.4059.

    Article  PubMed  CAS  Google Scholar 

  65. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 Investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32. https://doi.org/10.1056/NEJMoa1503093.

    Article  PubMed  CAS  Google Scholar 

  66. Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1(4):433–40. https://doi.org/10.1001/jamaoncol.2015.1184.

    Article  PubMed  Google Scholar 

  67. Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016;4(14):272. https://doi.org/10.21037/atm.2016.07.10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8. https://doi.org/10.1200/JCO.2014.58.3377.

    Article  PubMed  CAS  Google Scholar 

  69. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/−granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009;15(4):1443–51. https://doi.org/10.1158/1078-0432.CCR-08-1231.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16. https://doi.org/10.1056/NEJMoa1103782.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65. https://doi.org/10.1016/S0140-6736(12)60868-X.

    Article  PubMed  CAS  Google Scholar 

  72. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51. https://doi.org/10.1016/S0140-6736(15)60898-4.

    Article  PubMed  CAS  Google Scholar 

  73. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76. https://doi.org/10.1056/NEJMoa1408868.

    Article  PubMed  CAS  Google Scholar 

  74. Daud A, Gill J, Kamra S, Chen L, Ahuja A. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017;10(1):3. https://doi.org/10.1186/s13045-016-0369-8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34. https://doi.org/10.1001/jama.2011.746.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M, Schittek B. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol. 2007;156(6):1204–13. https://doi.org/10.1111/j.1365-2133.2007.07821.x.

    Article  PubMed  CAS  Google Scholar 

  77. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, Garbe C, Meier FE. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol. 2008;128(8):2013–23. https://doi.org/10.1038/jid.2008.44.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divine Dermatology and Surgical Institute, Fort Collins, CO, USA

    Jennifer Divine

  2. Dermatology, Vanderbilt University of Medicine, Nashville, TN, USA

    Anna S. Clayton

Authors
  1. Jennifer Divine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna S. Clayton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

    Allison Hanlon

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Divine, J., Clayton, A. (2018). Melanoma. In: Hanlon, A. (eds) A Practical Guide to Skin Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-74903-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-74903-7_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-74901-3

  • Online ISBN: 978-3-319-74903-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation